NGNE
Neurogene Inc.
$23.25
-0.70
(-2.92%)
Mkt Cap
367.40M
Volume
571,499
52W Range
15.93-43.66
Sector
Healthcare
Beta
2.09
EPS (TTM)
-5.51 USD
P/E Ratio
-4.86
Revenue (TTM)
0 USD
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
Neurogene Inc. is dedicated to engineering transformative genetic treatments for individuals and their families grappling with debilitating neurological conditions. Its current pipeline prominently features two key investigational therapies: NGN-401, an AAV9 gene therapy specifically targeting Rett syndrome, and NGN-101, which is being developed to address neuronal ceroid lipofuscinosis subtype 5 (Batten disease). The company's operations are based in New York, New York.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 925,000 | 0 | 0 | 0 | 0 | 0 | 25.00M | 0 | 0 | 0 | 0 |
| Net Income | (90.35M) | (75.14M) | (36.32M) | (55.19M) | (50.52M) | (33.28M) | (69.44M) | (31.59M) | (50.18M) | (37.00M) | (21.86M) | (23.82M) |
| EPS | -4.24 | -4.28 | -2.83 | -4.30 | -0.92 | -0.64 | -2.57 | -1.34 | -2.14 | -1.96 | -1.73 | -2.75 |
| Free Cash Flow | (78.36M) | (71.41M) | (51.74M) | (55.05M) | (64.77M) | (26.79M) | (16.27M) | (31.63M) | (45.21M) | (30.94M) | (20.30M) | (17.92M) |
| FCF / Share | -3.70 | -4.07 | -4.03 | -4.29 | -1.18 | -0.52 | -0.60 | -1.34 | -1.93 | -1.64 | -1.61 | -2.07 |
| Operating CF | (77.17M) | (70.60M) | (51.42M) | (52.82M) | (46.40M) | (24.57M) | (15.39M) | (31.58M) | (44.72M) | (30.23M) | (20.27M) | (17.81M) |
| Total Assets | 288.60M | 335.73M | 222.57M | 109.27M | 101.49M | 210.52M | 147.02M | 77.62M | 110.33M | 154.38M | 113.34M | 41.42M |
| Total Debt | 9.89M | 12.43M | 16.25M | 4.69M | 6.43M | 12.12M | 1.21M | 5,999 | 32,999 | 47,000 | 131,000 | 72,341 |
| Cash & Equiv | 103.84M | 136.59M | 148.21M | 82.02M | 70.54M | 192.56M | 143.09M | 76.93M | 52.03M | 32.30M | 39.53M | 14.91M |
| Book Value | 264.89M | 310.38M | 186.02M | 98.63M | (91.88M) | 191.22M | 141.69M | 72.67M | 98.89M | 144.66M | 108.42M | 36.15M |
| Return on Equity | -0.34 | -0.24 | -0.20 | -0.56 | N/A | -0.17 | -0.49 | -0.43 | -0.51 | -0.26 | -0.20 | -0.66 |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 925,000 | 0 | 0 | 0 |
| Net Income | (34.49M) | (30.93M) | (24.73M) | (20.95M) | (22.02M) | (22.65M) | (19.51M) | (20.22M) | (18.49M) | (16.92M) | 2.38M | (14.58M) |
| EPS | -1.53 | -1.39 | -1.60 | -0.99 | -1.05 | -1.08 | -1.31 | -1.19 | -1.09 | -1.00 | -1.21 | -0.41 |
| Free Cash Flow | (24.11M) | (26.40M) | (16.79M) | (19.81M) | (19.61M) | (21.55M) | (17.61M) | (15.73M) | (16.35M) | (21.71M) | (29.28M) | (11.65M) |
| FCF / Share | -1.07 | -1.18 | -1.08 | -0.94 | -0.93 | -1.03 | -1.19 | -0.93 | -0.97 | -1.28 | -2.28 | -1.05 |
| Operating CF | (23.76M) | (26.12M) | (16.67M) | (19.68M) | (19.46M) | (20.77M) | (17.50M) | (15.56M) | (15.89M) | (21.65M) | (29.52M) | (11.57M) |
| Total Assets | 244.36M | 263.14M | 289.18M | 287.83M | 297.32M | 315.30M | 335.73M | 164.12M | 179.82M | 195.35M | 222.57M | 89.59M |
| Total Debt | 8.35M | 9.13M | 9.89M | 11.27M | 12.85M | 13.54M | 12.43M | 14.53M | 13.79M | 14.41M | 16.25M | 11.47M |
| Cash & Equiv | 112.48M | 124.16M | 103.84M | 71.00M | 58.81M | 70.77M | 136.59M | 66.63M | 111.03M | 150.14M | 148.21M | 25.23M |
| Book Value | 217.13M | 237.78M | 264.89M | 265.54M | 273.25M | 291.80M | 310.38M | 137.41M | 155.01M | 170.78M | 186.02M | 75.23M |
| Return on Equity | -0.16 | -0.13 | -0.09 | -0.08 | -0.08 | -0.08 | -0.06 | -0.15 | -0.12 | -0.10 | 0.01 | -0.19 |
NGNE News
Neurogene (NASDAQ:NGNE) Sees Large Volume Increase – Should You Buy?
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Head-To-Head Comparison: Neurogene (NASDAQ:NGNE) & Applied Dna Sciences (NASDAQ:BNBX)
Bank of New York Mellon Corp Purchases New Position in Neurogene Inc. $NGNE
Neurogene to Participate in H.C. Wainwright 28th Annual Global Investment Conference
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BlackRock Inc. Invests $33.27 Million in Neurogene Inc. $NGNE
Neurogene Reports Second Quarter 2026 Financial Results and Highlights Recent Updates
Neurogene Reports Second Quarter 2026 Financial Results and Highlights Recent Updates
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)